Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Acquisitions & Divestments (2023 - 2024)

Historic Change in Acquisitions & Divestments for Lyra Therapeutics (LYRA) over the last 2 years, with Q4 2024 value amounting to $28.1 million.

  • Lyra Therapeutics' Change in Acquisitions & Divestments fell 4161.92% to $28.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $130.6 million, marking a year-over-year increase of 1777.14%. This contributed to the annual value of $130.6 million for FY2024, which is 1777.14% up from last year.
  • As of Q4 2024, Lyra Therapeutics' Change in Acquisitions & Divestments stood at $28.1 million, which was down 4161.92% from $21.0 million recorded in Q3 2024.
  • In the past 5 years, Lyra Therapeutics' Change in Acquisitions & Divestments ranged from a high of $51.0 million in Q2 2024 and a low of $9.8 million during Q1 2023